APA (7th ed.) Citation

Blomquist, M. R., Noviello, T. M. R., Sereduk, C., Grief, D., Caruso, F. P., Sharma, R., . . . Ceccarelli, M. (2025). Glioblastoma resistance to EGFR antibody-drug conjugate is driven by transcriptional reprogramming and TEK-induced EGFR suppression. Journal of Translational Medicine, 23(1), 1. https://doi.org/10.1186/s12967-025-07216-5

Chicago Style (17th ed.) Citation

Blomquist, Mylan R., et al. "Glioblastoma Resistance to EGFR Antibody-drug Conjugate Is Driven by Transcriptional Reprogramming and TEK-induced EGFR Suppression." Journal of Translational Medicine 23, no. 1 (2025): 1. https://doi.org/10.1186/s12967-025-07216-5.

MLA (9th ed.) Citation

Blomquist, Mylan R., et al. "Glioblastoma Resistance to EGFR Antibody-drug Conjugate Is Driven by Transcriptional Reprogramming and TEK-induced EGFR Suppression." Journal of Translational Medicine, vol. 23, no. 1, 2025, p. 1, https://doi.org/10.1186/s12967-025-07216-5.